For more than a decade the World Health Organization (WHO) has published a report highlighting the relevance of considering low adherence to treatment in health policy decisions and its marked economic and health consequences [9]
Liver Benefits: Combating Fatty Liver Disease Fatty liver disease, especially non-alcoholic steatohepatitis (NASH) , is on the rise and closely linked to obesity and insulin resistance
T., & Cooper, M
Market Restraints Drug Pricing, Supply Constraints, Gastrointestinal Tolerability, and Compounding Disruption Limit GLP-1 Market Scaling Drug pricing and affordability remain the most impactful near-term restraints for the GLP-1 Weight Loss Drug Market through 2030
Figures show dpm, mean sd for 5 replicate incubations.
Five pharmacy partners are disclosed by name: BPI Labs, Empower, Hallandale, OptioRx, and Red Rock